On June 1, 2026, the European Chemicals Agency (ECHA) launched a public consultation on a proposal submitted by Germany to revise the harmonised classification and labelling (CLH) of esbiothrin (CAS No. 260359-57-7) under the Classification, Labelling and Packaging (CLP) Regulation. The consultation will remain open until July 31, 2026, allowing stakeholders to submit comments and scientific information on the proposed hazard classifications. Germany has proposed strengthening the current classification of esbiothrin by classifying the substance as Acute Toxicity Category 3 (oral), Reproductive Toxicity Category 2 (suspected of damaging the unborn child), Specific Target Organ Toxicity – Single Exposure Category 1 (nervous system), and Specific Target Organ Toxicity – Repeated Exposure Category 2 (skin), while maintaining classifications for acute inhalation toxicity and aquatic hazards. The proposal also includes significantly higher aquatic hazard M-factors and the removal of esbiothrin from an existing group entry covering allethrin-related substances in Annex VI to the CLP Regulation. The consultation covers multiple hazard classes, including acute toxicity, reproductive toxicity, carcinogenicity, mutagenicity, skin sensitisation, specific target organ toxicity, aspiration hazard, and environmental hazards. Information received during the consultation will be evaluated by ECHA’s Committee for Risk Assessment (RAC) before an opinion is adopted and considered for inclusion in Annex VI to the CLP Regulation.
Consumer News Region